We review the role of cross-over trials in pharmacokinetic and pharmacodynamic studies, in particular as applied in phase I. Design and analysis considerations are covered. We also consider the use of pharmacokinetic and pharmacodynamic theories in planning cross-over trials. Finally some practical considerations are covered.
Get full access to this article
View all access options for this article.
References
1.
Senn SJ.Cross-over trials in clinical research. Chichester: John Wiley , 1993.
2.
Senn SJ.Statistical issues in drug development. Chichester: John Wiley , 1997.
3.
Kershner RP , Federer WT.Two-treatment cross-over designs for estimating a variety of effects . Journal of the American Statistical Association1981; 76: 612-619 .
4.
Lasker EM , Meisner M , Kushner HB.Optimal crossover designs in the presence of carryover effects . Biometrics1983; 39: 1089-1091 .
5.
Matthews JNS.Optimal cross-over designs for the comparison of two treatments in the presence of carry-over effects and autocorrelated errors . Biometrika1989; 74: 311-320 .
6.
Donev AN.Crossover designs with correlated observations . Journal of Biopharmaceutical Statistics1998; 8: 249-262 .
7.
Fleiss JL.A critique of recent research on the two-treatment cross-over design . Controlled Clinical Trials1989; 10: 1121-1130 .
8.
Senn SJ , and Lambrou D.Robust and realistic approaches to carry-over . Statistics in Medicine1989; 17: 2849-2864 .
9.
Boon PC and Roes KCB.Design and analysis issues for cross-over designs in phase I clinical studies . Journal of Biopharmaceutical Statistics1999; 9109-128 .
10.
Sheiner LB , Hasimoto Y , Beal SL.A simulation study comparing studies for dose ranging . Statistics in Medicine1991; 10: 303-322 .
11.
Senn SJ.Statisticians and pharmacokineticists: what can they learn from each other? In: Aarens L ed. COST B1 medicine: the population approach: measuring and managing variability in response, concentration and dose. Brussels: European Commission , 1997.
12.
Racine A , Grieve AP , Flühler H , Smith AFM.Bayesian methods in practice: experiences in the pharmaceutical industry (with discussion) . Applied Statistics1986; 35: 93-150 .
13.
Martin A , Browning RC.Metoprolol in the aged hypertensive: a comparison of two dosage schedules . Postgraduate Medical Journal1985; 61: 225-227 .
14.
Tett SE , Holford NHG , McLachlan AJ.Population pharmacokinetics and pharmacodynamics: an underutilized resource , Drug Information Journal1998; 32: 693-710 .
15.
Rowland M , Tozer TN.Clinical pharmacokinetics: concepts and applications, 3rd edn.Baltimore, MD: William & Wilkins , 1995.
16.
Matthews JNS.Multi-period cross-over trials . Statistical Methods in Medical Research1994; 3: 383-405 .
Jones B , Donev AN.Modelling and design of cross-over trials . Statistics in Medicine1996; 15: 1435-1446 .
19.
Davidian M , Giltinan DM.Nonlinear models for repeated measurement data. London: Chapman & Hall , 1995.
20.
Jones B , Wang J , Jarvis P , Byrom W.Design of cross-over trials for pharmacokinetic studies , Journal of Statistical Planning and Inference1999; 78: 307-316 .
21.
Fedorov VV.Theory of optimal experiments. New York: Academic Press , 1972.
22.
Steinijans VW , Hauschke D , Schall, R.International harmonization of regulatory requirements for average bioequivalence and current issues in individual bioequivalence . Drug Information Journal1995; 29: 1055-1062 .
23.
Anderson S , Hauck WW.Consideration of individual bioequivalence . Journal of Pharmacokinetics and Biopharmaceutics1990; 18: 259-273 .
24.
Shumaker RC , Metzler CM.The phenytoin trial is a case study of `individual' bioequivalence . Drug Information Journal1998; 32: 1063-1072 .
25.
Senn SJ.In the blood: proposed new requirements for registering generic drugs . The Lancet1998; 352: 85-86 .
26.
Dette H , Munk, A.Optimum allocation of treatments for Welch's test in equivalence assessment . Biometrics1997; 53: 1143-1150 .
27.
Senn SJ , Grieve AP.A comment on optimal allocations for bioequivalence studies . Biometrics1999; in press.
28.
Freeman PR.The performance of the two-stage analysis of two-treatment, two-period crossover trials . Statistics in Medicine1989; 8: 1421-1432 .
29.
Senn SJ.The AB/BA cross-over: how to perform the two stage analysis if you can't be persuaded that you shouldn't. In: Hansen, B , de Ridder M eds. Liber Amicorum Roel van Strik. Rotterdam , 1996.
30.
Gould AL.Interim analyses for monitoring clinical trials that do not materially affect the type I error rate . Statistics in Medicine1992; 11: 55-66 .
31.
Gould AL.Group sequential extensions of a standard bioequivalence testing procedureJournal of Pharmacokinetics and Biopharmaceutics1995; 23: 57-86 .
32.
Gough K , Hutchison M , Keene O , Byrom B , Ellis S , Lacey L , McKeller J.Assessment of dose proportionality: report from the statisticians in the pharmacetical industry/pharmacokinetics UK joint workin party . Drug Information Journal1995; 29: 1039-1048 .
